NMR relaxometric properties and cytotoxicity of Gd2O3 nanoparticle suspensions in an organic liquid
АуториBabić-Stojić Branka S.
Jokanović, Vukoman R.
Arsikin, Katarina M.
Чланак у часопису
МетаподациПриказ свих података о документу
Gd2O3 nanoparticles and their agglomerates from approximately 10 to 80 nm in size suspended in an organic liquid were synthesized via polyol route. The reaction between diethylene glycol and added acetic acid, which occurred simultaneously with the synthesis of Gd2O3 nanoparticles, was catalyzed by sodium bisulfate to transform as much as possible diethylene glycol in corresponding ester at the end of complete reaction. The produced nanosized material of gadolinium oxide was investigated by TEM, DLS, FTIR spectroscopy, and NMR relaxometry. Biological evaluation of this material was done by MTT and crystal violet assays to determine the cell viability. Longitudinal and transverse relaxivities of water-diluted Gd2O3 nanoparticle suspensions estimated to be r(1) = 13.6 and r(2) = 14.7 s(-1) mM(-1) are about three times higher compared to the relaxivities obtained for standard contrast agent Gd-DTPA (Magnevist). Good MRI signal intensities of the water-diluted Gd2O3 nanoparticle suspension...s were recorded in the Gd concentration range 0.2-0.3 mM for which the suspensions were not toxic exhibiting simultaneously higher signal intensities than those for Magnevist in the Gd concentration range 0.4-1 mM for which this standard contrast agent was not toxic. These properties make the produced Gd2O3 nanoparticle material promising for potential application as MRI contrast agent.
Кључне речи:Gadolinium oxide / Nanoparticles / Relaxivity / Magnetic resonance imaging / Contrast agents / Toxicity / Environmental and health effects
Извор:Journal of Nanoparticle Research, 2014, 16, 10
- Хемијско и структурно дизајнирање наноматеријала за примену у медицини и инжењерству ткива (RS-172026)
- Модулација сигналних путева који контролишу интрацелуларни енергетски баланс у терапији тумора и неуро-имуно-ендокриних поремећаја (RS-41025)
ISSN: 1388-0764 (print); 1572-896X (electronic)